Melanoma News and Research

Latest Melanoma News and Research

DUSA Pharmaceuticals receives notice of allowance for patent covering blue light technology

DUSA Pharmaceuticals, Inc.®, a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office has issued a notice of allowance for a key patent related to its proprietary PDT light source, the BLU-U®, Blue Light Photodynamic Therapy Illuminator.

7 May 2010

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.

6 May 2010

Vical reports net loss of $8.5 million for first-quarter 2010

Vical Incorporated today reported financial results for the quarter ended March 31, 2010. Revenues were $1.5 million for the first quarter of 2010 compared with $2.3 million for the first quarter of 2009, reflecting lower revenues under the company's license agreement with AnGes MG, Inc. Operating expenses were $10.1 million for the first quarter of 2010 compared with $10.6 million for the first quarter of 2009.

6 May 2010

Multistage nanovector system for siRNA delivery lengthens therapeutic effects of ovarian cancer treatment

New research by scientists at The University of Texas Health Science Center at Houston (UTHealth) and The University of Texas M. D. Anderson Cancer Center could make it easier for patients to use a family of promising experimental cancer therapeutics known as small interfering RNA (siRNA).

6 May 2010

New study reveals facial skin cancer occurs predominantly on left-side

In a study appearing in the Journal of the American Academy of Dermatology a Saint Louis University doctor found that facial skin cancers were predominantly on the left-side, and especially in men.

6 May 2010

UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announced at BIO2010 in Chicago that its proposal to conduct a Phase I clinical trial on SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma, has been approved in the UK by the Gene Therapy Advisory Committee and by the Medicines and Healthcare products Regulatory Agency Medicines Division.

5 May 2010

UVA exposure at early age does not cause melanoma

Early life exposure to ultraviolet A light does not cause melanoma in a fish model that previously made that connection, scientists from The University of Texas MD Anderson Cancer Center reported today in the online Early Edition of the Proceedings of the National Academy of Sciences.

5 May 2010

Celldex reports net loss of $6.6 million for first-quarter 2010

Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.

4 May 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended March 31, 2010.

4 May 2010

MicroStockProfit.com releases investment report on Vical

MicroStockProfit.com announces an investment report featuring Vical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

4 May 2010

Skin cancer rates going down in Alberta: Research group

It appears that people are listening to doctors' orders to protect their skin from the sun. In the largest Canadian study of non-melanoma skin cancer, Andrei Metelitsa, Gordon Jung and their research group have found skin cancer rates in Alberta are going down in men and have levelled off for women. This comes at a time when American scientists say that skin cancer rates are on the rise.

4 May 2010

HTG, JWCI collaborate to develop new approaches for early stage primary cutaneous melanoma diagnosis

HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™), today announced it signed a collaboration agreement with the John Wayne Cancer Institute (JWCI) at Saint John's Health Center in Santa Monica, California. Under the terms of the agreement, HTG and JWCI (Department of Molecular Oncology, Dave S. B. Hoon, Ph.D., Director) will collaborate to generate a novel mRNA signature that can measure the gene expression differences in melanoma and benign nevi using HTG's qNPA technology in classical surgical pathology samples.

3 May 2010

AVEENO Brand partners with The Skin Cancer Foundation for Road to Healthy Skin Tour program

To coincide with Skin Cancer Awareness Month, the AVEENO Brand announces its third-year partnership with The Skin Cancer Foundation for the Road to Healthy Skin Tour, a program that has been instrumental in educating people nationwide about skin cancer detection and prevention. This year, the Tour will visit over 80 locations through September.

3 May 2010

FDA oks 'vaccine' to treat prostate cancer

Provenge, developed by Dendreon Corporation, is the first approved "treatment that uses a so-called cancer vaccine, a drug that trains the body's own immune system to fight the disease," The New York Times reports.

3 May 2010

Hartford, Salt Lake City and Denver outshine other U.S. cities on skin cancer awareness

At first glance, Hartford, Salt Lake City and Denver might not seem to have much in common. But a new survey by the American Academy of Dermatology (Academy) found these three cities outshine other U.S. cities in heeding dermatologists' advice on preventing and detecting skin cancer.

3 May 2010

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

Studies and analyses of the Crohn’s Disease (CD) treatment Cimzia® (certolizumab pegol) demonstrating new data will be exhibited at Digestive Disease Week (DDW) 2010, taking place in New Orleans from May 1-5, 2010.

30 Apr 2010

TenX Biopharma signs Clinical Trial Agreement with NCI

TenX Biopharma, Inc., announced today it has signed a Clinical Trial Agreement with the National Cancer Institute to conduct an investigator sponsored Phase II clinical trial.

30 Apr 2010

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the first quarter of 2010.

30 Apr 2010

FDA approves Provenge prostate cancer vaccine

Cancer may now be fought with a vaccine. The FDA has finally approved an immune boosting vaccine which is said to extend survival of patients at an advanced stage of prostate cancer by four months. This is twice as long as what could be expected with regular chemotherapy. There is also an increase of three years survival after detection in initial stage by 38% thanks to the vaccine.

30 Apr 2010